Male pseudohermaphroditism and pure gonadal dysgenesis in sisters.

M. Barr,D. Carr,E. Plunkett,H. Soltan,R. G. Wiens

DOI: https://doi.org/10.1016/0002-9378(67)90342-0

IF: 9.8

1967-12-15

American Journal of Obstetrics and Gynecology

Abstract:

What problem does this paper attempt to address?

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Yanwei Wang,Xinmin Lou,Xiaomin Xu,Jianhua Zhu,Yunpeng Shang

DOI: https://doi.org/10.1016/j.jjcc.2016.12.019

IF: 2.974

2017-01-01

Journal of Cardiology

Abstract:Objectives: The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) with drug eluting stents (DES) in patients with in-stent restenosis (ISR). Background: DES implantation and DEB were available strategies in percutaneous coronary intervention (PCI) for ISR, but the optimal management for ISR lesions remains controversial. Methods: Electronic databases were searched for randomized controlled trials and observational cohort studies which reported the clinical outcomes of using DEB comparing with DES implantation in patients with ISR. Clinical endpoints such as major adverse cardiovascular events (MACE), death, and myocardial infarction were assessed. Results: Five randomized controlled trials and five observational cohort studies with 962 patients in the DEB group and 908 patients in the DES group met inclusion criteria. There was no significant difference between DEB and DES in major clinical outcomes, such as MACE (OR 1.01; 95% Cl: 0.64-1.58; p = 0.97; I-2 = 0%), all-cause death (OR 1.04; 95% CI: 0.54-1.98; p = 0.91; I-2 = 0%), cardiovascular death (OR 1.44; 95% CI: 0.57-3.65; p = 0.44; I-2 = 0%), stent thrombosis (OR 0.61; 95% Cl: 0.16-2.33; p = 0.47; I-2 = 0%), and myocardial infarction (OR 1.02; 95% CI: 0.53-1.94; p = 0.96; I-2 = 0%). DEB was associated with a significant increase in target lesion revascularization (OR 1.54; 95% CI: 1.10-2.15; p = 0.01; I-2 = 57%). Conclusion: Treatment of ISR using DEB led to comparable clinical outcomes with DES implantation. (C) 2017 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Wang Chong-hui,Fang Quan,Zhang Shu-yang,Shen Zhu-jun,Fan Zhong-jie,Jin Xiao-feng,Zeng Yong,Liu Zhen-yu,Xie Hong-zhi,Yang Ming

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.16.001

IF: 6.133

2012-01-01

Chinese Medical Journal

Abstract:Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician's discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.Results The clinical follow-up duration was 3 years ((41.7 +/- 16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P>0.05).Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. Chin Med J 2012;125(16):2803-2806
Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis

J Krefting,N Krueger,C Graesser,R Schmieder,F Starnecker,S Kufner,S Cassese,A Kastrati,H Schunkert,M Von Scheidt,J Wiebe

DOI: https://doi.org/10.1093/eurheartj/ehae666.1459

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Coronary in-stent restenosis (ISR) poses a significant challenge in interventional cardiology, with optimal treatment strategies being the subject of ongoing debate. Current clinical guidelines offer a choice between drug-coated balloon angioplasty (DCB) and repeat stenting with second-generation drug-eluting stents (DES), each with distinct implications for long-term patient outcomes. Purpose The aim of this study is to compare 1-year outcomes between DCB angioplasty and second-generation DES in the treatment of ISR. Longitudinal real-world data are used from the OBSERVABLE database, which comprises German health claims data between 2012 and 2021. Methods A total of 10,440 ISR individuals undergoing DCB or DES intervention were identified. After exclusion of bare-metal stents, first generation stents and non-DCBs, 3,810 propensity score-matched individuals remained. The primary outcome was the composite of all-cause mortality and myocardial infraction (MI). Secondary outcomes included all-cause death, MI, and bleeding as a safety outcome. Results At 1-year follow-up, the primary outcome of all-cause mortality and MI was observed in 246 individuals (12.9%) in the DES group, compared with 201 individuals (10.6%) in the DCB group (HR, 1.27; 95% CI, 1.06-1.53). Sensitivity analysis confirmed the robustness of these findings. Secondary outcomes revealed higher all-cause mortality in the DES group (7.9%) compared to the DCB group (6.3%) (HR, 1.31; 95% CI, 1.03-1.66), with no difference in MI. Bleeding events were comparable between the two treatments, with 244 individuals (12.8%) in the DES group and 206 individuals (10.8%) in the DCB group (HR, 1.17; 95% CI, 0.89-1.53). Conclusion This real-world data analysis demonstrated a higher incidence of the primary composite endpoint of all-cause mortality and MI within one year, after treatment with DES compared to DCB. Our results support prior findings about the safety profile of repeated DES implantation and strengthen DCB as a potential superior alternative to DES in ISR management.

cardiac & cardiovascular systems
Ten-year major clinical outcomes between first- and second-generation drug-eluting stents in hypertensive patients underwent percutaneous coronary intervention

S Rha,S Y Choi,B G Choi,J Cha,S Hyun,J Kang,W Chu,S Park,C U Choi,C G Park

DOI: https://doi.org/10.1093/eurheartj/ehae666.2546

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background There are very limited long-term clinical outcome data comparing first-generation (1G) versus second-generation (2G) drug-eluting stents (DES) in patients with hypertension. The authors sought to compare the efficacy and safety 2G-DES with 1G-DES in hypertension patients who underwent percutaneous coronary intervention (PCI) during ten-year clinical follow-up periods. Methods Finally, a total of 1,631 eligible hypertensive patients who underwent PCI with 1G-DES (paclitaxel-, sirolimus-eluting stent, n = 715) or 2G-DES (zotarolimus [endeavor, endeavor resolute]- or everolimus-eluting stent [promus element, xience], n = 916) were enrolled. The study endpoints were individual and composite clinical outcomes up to ten-year. Results After PSM, two propensity-matched (PSM) groups (452 pairs) were generated. During the ten-year follow-up period, the 2G-DES group had a lower incidence of target lesion revascularization (TLR; hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.35 – 0.82; p = 0.004), target vessel revascularization (TVR; HR, 0.66; 95% CI, 0.46 – 0.94; p = 0.022), any revascularization (HR, 0.65; 95% CI, 0.48 – 0.88; p = 0.006), total major adverse cardiac events (MACE; HR, 0.70; 95% CI, 0.55 – 0.90; p = 0.005), TLR MACE (HR, 0.69; 95% CI, 0.49 – 0.98; p = 0.037), and MACCE (HR, 0.69; 95% CI, 0.54 – 0.88; p = 0.002, table). Conclusion In our single-center, all-comer registry, 2G-DES had better efficacy especially repeat revascularization and MACE as compared with 1G-DES in hypertensive patients during 10-year follow-up periods.

cardiac & cardiovascular systems
Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.

Jian-Feng Zheng,Ting-Ting Guo,Yuan Tian,Yong Wang,Xiao-Ying Hu,Yue Chang,Hong Qiu,Ke-Fei Dou,Yi-Da Tang,Jin-Qing Yuan,Yong-Jian Wu,Hong-Bing Yan,Shu-Bin Qiao,Bo Xu,Yue-Jin Yang,Run-Lin Gao

DOI: https://doi.org/10.1097/cm9.0000000000001135

2020-01-01

Abstract:Abstract. Background:. The mechanism and characteristics of early and late drug-eluting stent in-stent restenosis (DES-ISR) have not been fully clarified. Whether there are different outcomes among those patients being irrespective of their repeated treatments remain a knowledge gap. Methods:. A total of 250 patients who underwent initial stent implantation in our hospital, and then were readmitted to receive treatment for the reason of recurrent significant DES-ISR in 2016 were involved. The patients were categorized as early ISR (<12 months; E-ISR; n = 32) and late ISR (≥12 months; L-ISR; n = 218). Associations between patient characteristics and clinical performance, as well as clinical outcomes after a repeated percutaneous coronary intervention (PCI) were evaluated. Primary composite endpoint of major adverse cardiac events (MACEs) included cardiac death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR). Results:. Most baseline characteristics are similar in both groups, except for the period of ISR, initial pre-procedure thrombolysis in myocardial infarction, and some serum biochemical indicators. The incidence of MACE (37.5% vs. 5.5%; P < 0.001) and TLR (37.5% vs. 5.0%; P < 0.001) is higher in the E-ISR group. After multivariate analysis, E-ISR (odds ratio [OR], 13.267; [95% CI 4.984–35.311]; P < 0.001) and left ventricular systolic dysfunction (odds ratio [OR], 6.317; [95% CI 1.145–34.843]; P = 0.034) are the independent predictors for MACE among DES-ISR patients in the mid-term follow-up of 12 months. Conclusions:. Early ISR and left ventricular systolic dysfunction are associated with MACE during the mid-term follow-up period for DES-ISR patients. The results may benefit the risk stratification and secondary prevention for DES-ISR patients in clinical practice.
Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials

Yong Zhu,Kesen Liu,Xiangyun Kong,Jing Nan,Ang Gao,Yan Liu,Hongya Han,Hong Li,Huagang Zhu,Jianwei Zhang,Yingxin Zhao

DOI: https://doi.org/10.3389/fcvm.2021.766088

IF: 3.6

2021-12-01

Frontiers in Cardiovascular Medicine

Abstract:Introduction: In-stent restenosis (ISR) remains a challenging issue despite the great advance of drug-eluting stents (DES). In addition, the consensus was lacking regarding the optimal strategy for DES-ISR. Therefore, we aimed to evaluate angiographic and clinical outcomes of the two most effective treatments DES vs. drug-eluting balloon (DCB) for patients with DES-ISR. Methods: This meta-analysis used the data from the randomized controlled trials (RCTs), which were identified by a systematic search in the databases of PubMed, Embase, and Cochrane Library. Target lesion revascularization (TLR) was regarded as the primary endpoint. In addition, the late angiographic outcomes and other clinical outcomes, namely, cardiac death, myocardial infarction (MI), target vessel revascularization, stent thrombosis, and major adverse cardiac events, were also included for analysis. Results: Five RCTs with about 1,193 patients were included in this meta-analysis for the analysis. For the primary endpoint, the overall pooled outcomes suggested repeat DES implantation was associated with a significant reduction in the term of TLR compared with DCB angioplasty (risk ratio = 1.53, 95% CI 1.15–2.04, p = 0.003). But no significant difference in angiographic outcomes and other clinical endpoints were observed between DES and DCB. In the subgroup analysis, DCB was inferior to new-generation DES (NG-DES)/everolimus-eluting stent (EES) in the term of TLR. In addition, this non-significant trend was also noted in the subgroup of the paclitaxel-eluting stent (PES) vs. DCB. For the angiographic endpoints, EES, not PES, was associated with larger minimum lumen diameter [mean difference (MD) = −0.25, 95% CI −0.38 to −0.11, p = 0.0003], lower percent diameter stenosis (MD = 7.29%, 95% CI 2.86–11.71%, p = 0.001), and less binary restenosis (OR = 2.20, 95% CI 1.18–4.11, p = 0.01). But NG-DES/EES was comparable to DCB in cardiac death, MI, and stent thrombosis. Conclusions: For the patients with DES-ISR, treatment with DES, especially NG-DES/EES could reduce the risk of TLR significantly compared to DCB at long-term follow-up.

cardiac & cardiovascular systems
Comparison of Drug-Eluting Stents with Bare Metal Stents Implantation for the Treatment of Acute ST-elevation Myocardial Infarction: 2-Year Clinical Outcomes from Single-Center Registry.

Li Yi,Han Ya-ling,Zhang Quan-yu,Guan Shao-yi,Wang Xiao-zeng,Jing Quan-min,Ma Ying-yan,Wang Geng,Wang Bin,Deng Jie

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2011.06.005

2011-01-01

Abstract:Background Some larger scale, randomized studies have demonstrated the superiority of drug-eluting stents (DES) over bare metal stents (BMS) for the treatment of acute myocardial infarction (AMI). This study aimed to investigate the impact of DES, in comparison with BMS, on the 2-year clinical outcomes in patients with ST-elevation myocardial infarction (STEMI).Methods From January 2002 to December 2008, a total of 1301 consecutive STEMI patients treated with coronary stenting in Shenyang Northern Hospital were prospectively registered. Patients received BMS (n=868) or DES (n=435) implantation in the infarction related artery according to physician's discretion. A propensity score analysis was performed and two well matched subgroups were selected (BMS, n=288; DES, n=288) to evaluate the 2-year clinical outcomes. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of all-cause death, myocardial infarction (MI), or target vessel revascularization (TVR).Results Survival salvage analysis showed that 2-year cumulative hazards were not significantly different between the two groups with respect to TVR (2.8% vs. 3.1%, log-rank P=0.780), stent thrombosis (1.7% vs. 4.2%, log-rank P=0.079) and MACE (8% vs. 10.8%, log-rank P=0.236). Multivariate analysis showed that DES was an independent protective factor of MI (HR: 0.211, 95% Cl: 0.049 to 0.908) and stent thrombosis (HP: 0.327, 95% Cl: 0.107 to 0.994).Conclusion DES was associated with similar 2-year clinical outcomes to those of BMS for the treatment of STEMI in daily practice. Chin Med J 2011;124(6):825-830
Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

Zheng KUAI,Bing FAN,Liping BO,Juying QIAN,Qibing WANG,Lei GE,Junbo GE

DOI: https://doi.org/10.3969/j.issn.1008-6358.2011.05.014

2011-01-01

Abstract:Objective:To evaluate the curative effect of drug eluting stent(DES) implantation in the treatment of in-stent restenosis(ISR).Methods: A total of 63 patients were observed major adverse cardiac event(MACE) in the treatment of ISR after DES implantation during an average 22-month follow-up.Results: The MACE rate was 46.5% and no in-stent thrombosis or myocardial infraction occurred.The curative effect of post-DES ISR was better than post-bare metal stent(BMS)ISR.Logistic regression analysis revealed that there was no correlation between the long-term curative effect and age,gender,severity of lesion,vessel diameter,the drug eluting material or the type of former stent implantation.Conclusions: DES implantation is a safety and useful method in the treatment of ISR.
Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis

Wojciech Wańha,Sylwia Iwańczyk,Rafał Januszek,Rafał Wolny,Brunon Tomasiewicz,Wiktor Kuliczkowski,Krzysztof Reczuch,Paweł Pawlus,Tomasz Z. Pawłowski,Łukasz Kuźma,Piotr Kubler,Piotr Niezgoda,Jacek Kubica,Robert J. Gil,Tomasz F. Pawłowski,Mariusz Gąsior,Miłosz Jaguszewski,Maciej Wybraniec,Adam Witkowski,Mariusz Kowalewski,Fabrizio D'Ascenzo,Antonio Greco,Stanisław Bartuś,Maciej Lesiak,Marek Grygier,Wojciech Wojakowski,Bernardo Cortese

DOI: https://doi.org/10.1161/circinterventions.124.014064

2024-07-27

Circulation Cardiovascular Interventions

Abstract:Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Evidence suggests that drug-coated balloons may benefit in-stent restenosis (ISR) treatment. However, the efficacy of new-generation sirolimus-coated balloon (SCB) compared with the latest generation drug-eluting stents (DESs) has not been studied in this setting.METHODS:All patients in the EASTBORNE (The All-Comers Sirolimus-Coated Balloon European Registry) and DEB-DRAGON (DEB vs Thin-DES in DES-ISR: Long Term Outcomes) registries undergoing percutaneous coronary intervention for DES-ISR were included in the study. The primary study end point was target lesion revascularization at 24 months. Secondary end points were major adverse cardiovascular events, all-cause death, myocardial infarction, and target vessel revascularization at 24 months. Our goal was to evaluate the efficacy and safety of SCB versus thin-struts DES in ISR at long-term follow-up.RESULTS:A total of 1545 patients with 1679 ISR lesions were included in the pooled analysis, of whom 621 (40.2%) patients with 621 lesions were treated with thin-strut DES and 924 (59.8%) patients with 1045 lesions were treated with SCB. The unmatched cohort showed no differences in the incidence of target lesion revascularization (10.8% versus 11.8%;P=0.568); however, there was a trend toward lower rates of myocardial infarction (7.4% versus 5.0%;P=0.062) and major adverse cardiovascular events (20.8% versus 17.1%;P=0.072) in the SCB group. After propensity score matching (n=335 patients per group), there were no significant differences in the rates of target lesion revascularization (11.6% versus 11.8%;P=0.329), target vessel revascularization (14.0% versus 13.1%;P=0.822), myocardial infarction (7.2% versus 4.5%;P=0.186), all-cause death (5.7% versus 4.2%;P=0.476), and major adverse cardiovascular event (21.5% versus 17.6%;P=0.242) between DES and SCB treatment.CONCLUSIONS:In patients with ISR, angioplasty with SCB compared with thin-struts DES is associated with comparable rates of target lesion revascularization, target vessel revascularization, myocardial infarction, all-cause death, and major adverse cardiovascular events at 2 years.

cardiac & cardiovascular systems
Protease‐catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix‐assisted laser desorption/ionization mass spectrometry

M. Schnölzer,P. Jedrzejewski,W. Lehmann

DOI: https://doi.org/10.1002/elps.1150170517

Electrophoresis

Abstract:Proteins were digested in normal and highly 18O‐enriched water using proteases commonly employed for protein sequencing. The extent of 18O incorporation into the resulting peptide fragments was characterized by electrospray ionization (ESI) and matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS). The endoproteinases trypsin, Lys‐C and Glu‐C incorporate two atoms of 18O, resulting in a mass shift of +4 D for the peptide fragments. This indicates that, following proteolytic cleavage, peptide products continue to interact with these proteases and undergo repeated binding/hydrolysis cycles, resulting in complete equilibration of both oxygens in the carboxy terminus of the fragments with oxygen from solvent water. In contrast, chymotrypsin and Asp‐N incorporate only one atom of 18O, resulting in a mass shift of +2 D, indicating that after the cleavage step these proteases do not accept the peptides as substrates. In addition, it was found that the proteases trypsin, Glu‐C, and Lys‐C exhibit minor or nontypical sequence specificities, resulting in unexpected peptide fragments. These fragments incorporate only one 18O atom, indicating that they do not undergo further binding/hydrolysis cycles with the enzyme. Thus, it is possible to discriminate between enzyme‐typical peptide fragments with mass shifts of +4 D and nontypical fragments with mass shifts of only +2 D. Based on these observations, protein digest strategies are described for the generation of 1:1 ion doublets spaced either by 2 or 4 D. In addition, the C‐terminus of a protein can be identified by the absence of an ion doublet in the corresponding peptide fragment. In protein sequencing by mass spectrometry, digest protocols generating ion doublets provide the most clear‐cut analytical results for the recognition of ion series in ESI‐MS/MS and MALDI post‐source decay (PSD) product ion specta. Only the mass spectrometric fragment ions of a C‐terminal series show ion doublets spaced either by 2 or 4 D, whereas the fragment ions belonging to an N‐terminal series remain unshifted. This assignment unequivocally reveals the direction of the identified sequence.
Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis

Haifang Xie,Miaohan Qiu,Xinyan Li,Yao Xiao,Yanyan Mu,Geng Wang,Yaling Han

DOI: https://doi.org/10.1016/j.ijcard.2024.132450

2024-08-13

Abstract:Background: Drug-coated balloon (DCB) angioplasty and drug-eluting stents (DES) are two widely used treatments for in-stent restenosis (ISR). Focal and non-focal types of ISR affect the clinical outcomes. The present study aims to compare DES reimplantation versus DCB angioplasty in acute coronary syndrome (ACS) patients with focal ISR and non-focal ISR lesions. Methods: Patients with ISR lesions underwent percutaneous coronary intervention (PCI) were retrospectively evaluated and divided into DES group and DCB group. The primary endpoint was the incidence of target lesion failure (TLF) at 24 months follow up. Propensity score matching (PSM) was conducted to balance the baseline characteristics. Results: For focal ISR, TLF was comparable in the DES and DCB groups at 24 months of follow-up (Before PSM, hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.39-1.27; p = 0.244; After PSM, HR: 0.83; 95% CI: 0.40-1.73; p = 0.625). For non-focal ISR, TLF was significantly decreased in DES compared with DCB group (Before PSM, HR: 0.43; 95% CI: 0.29-0.63; p < 0.001; After PSM, HR: 0.33; 95% CI: 0.19-0.59; p < 0.001), which was mainly attributed to the lower incidence of clinically indicated target lesion revascularization (CD-TLR) (Before PSM, HR: 0.39; 95% CI: 0.26-0.59; p < 0.001; After PSM, HR: 0.28; 95% CI: 0.15-0.54; p < 0.001). Conclusions: The clinical outcomes for DES and DCB treatment are similar in focal type of ISR lesions. For non-focal ISR, the treatment of DES showed a significant decrease in TLF which was mainly attributed to a lower incidence of CD-TLR.
Comparison of Clinical Outcomes Between Second-and First-Generation Drug-Eluting Stents in Patients With Chronic Total Occlusion Lesion: A Meta-Analysis

Xuan Qiao,Wen-Jiao Zhang,Wen-Fen Guo,Yan Li,Xi-Ying Liang,Zhi-Lu Wang

DOI: https://doi.org/10.3389/fcvm.2021.598046

IF: 3.6

2021-04-20

Frontiers in Cardiovascular Medicine

Abstract:Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superior to first-generation ones in patients with chronic total occlusion lesion undergoing percutaneous coronary intervention. The study aimed to compare the differences in clinical outcomes between the two generations drug-eluting stents in patients with those by a meta-analysis. Methods: PubMed, Embase, the Cochrane library and Web of science databases were systemically searched before March, 2021. Randomized controlled trials and observational studies were included to compare the second-generation drug-eluting stents with the first-generation ones in patients with chronic total occlusion lesion undergoing percutaneous coronary intervention. The clinical outcomes were major adverse cardiac events (MACE), target vessel revascularization, myocardial infarction, all-cause death. Fixed effects models were used to calculate the odds ratio (OR) and 95% confidence interval (CI) of each clinical outcome. Sensitivity analysis was performed to detect potential sources of heterogeneity. Subgroup analyses were used to assess the differential effects. Results: The meta-analysis included eight studies involving 4,583 patients with chronic total occlusion lesion undergoing percutaneous coronary intervention. Pooled analysis showed that the incidence of MACE (OR = 0.68, 95%CI 0.54–0.85, P = 0.0008), target vessel revascularization (OR = 0.70, 95%CI 0.54–0.91, P = 0.007), and myocardial infarction (OR = 0.58, 95%CI 0.37–0.93, P = 0.02) were lower in the second-generation drug-eluting stents compared with the first-generation ones. However, there was not difference in all-cause deaths between two drug-eluting stents (OR = 0.67, 95%CI 0.45–1.01, P = 0.05). Conclusions: The second-generation drug-eluting stents are associated with lower MACE, target vessel revascularization, and myocardial infarction compared with the first-generation ones in patients with chronic total occlusion lesion undergoing percutaneous coronary intervention. The results of this study can provide a reference for the selection of stents in patients with chronic total occlusion lesion. Further randomized controlled trials are needed to verify that the second-generation drug-eluting stents is superior to the first-generation ones in patients with chronic total occlusion (Registered by PROSPERO, CRD42020158406).

cardiac & cardiovascular systems
Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis

Keqin Chen,Lei Xu,Xiehong Liu

DOI: https://doi.org/10.1007/s11239-023-02932-5

2024-01-29

Journal of Thrombosis and Thrombolysis

Abstract:Drug-eluting stents (DESs) have become the first-line treatment for symptomatic peripheral arterial disease (PAD). Currently, there are many types of DESs on the market. The same type of DESs has different concentrations, and various drugs in them show uneven efficacy. The selection of DESs remains controversial. This study was aimed at comparing the long-term real-world outcomes of different DESs in the treatment of peripheral arterial occlusive disease (PAOD). The databases including Cochrane Library, Embase, and PubMed were searched with a time frame until March 25, 2023. The primary patency (PP) and target lesion revascularization (TLR) at 6 months were used as the primary endpoints. A total of 32 studies (5467 patients) were eligible. At the six-month follow-up, DES-Evero 1 ug/mm2 ranked first in terms of PP, with a significant difference from BMSs (RR [95% CI] = 1.6). DES-Siro 0.9 ug/mm2, DES-Siro 1.4 ug/mm2, DES-Siro 1.95 ug/mm2, DES-PTX 0.167 ug/mm2, DES-PTX 1 ug/mm2 and covered stents (CSs) showed significantly better PPs than BMSs. In terms of TLR, DES-Siro 0.9 ug/mm2 (0.31) ranked first, and DES-Evero 1 ug/mm2 ranked last. Among the treatment modalities for PAD, different DESs showed overall encouraging results in improving PP and TLR compared with BMSs. DES-Evero 1 ug/mm2 showed the best PP, but it had the highest reintervention rate at 6 months. Sirolimus-eluting stents were not always more effective with higher concentrations of sirolimus. Among various DESs, sirolimus-eluting stents and everolimus-eluting stents were superior to paclitaxel-eluting stents.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Second-generation Versus First-Generation Drug-Eluting Stents in Saphenous Vein Graftdisease: A Meta-Analysis of Randomized Controlled Trials.

Hong-Tao Shi,Hong-Xia Chu,Wei Gu,Xin-Yong Cai,Jun-Jie Guo,Zhao-Gang Ding,Wei Gao,Lei-Lei Ma,Jian-Bing Zhu,Hai-Bo Liu,Zhe-Yong Huang,Qi-Bing Wang,Jun-Bo Ge,Shao-Jun Wen

DOI: https://doi.org/10.1016/j.ijcard.2016.03.228

IF: 4.039

2016-01-01

International Journal of Cardiology

Abstract:BACKGROUND:Second-generation drug-eluting stents (DESs) have become increasingly popular devices for patients with saphenous vein graft (SVG) disease. Second-generation DESs were designed to have more safety and efficacy than first-generation DES, but clinical outcomes in SVG disease remain conflicting.METHODS AND RESULTS:Randomized controlled trials (RCTs) were identified when comparing second- versus first-generation DESs in SVG disease. The main endpoint was all-cause death. The time of follow-up was at least 30days. The secondary endpoints were major adverse cardiovascular events (MACEs), target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI), and stent thrombosis. These endpoints were assessed at 30days, 12months and 24months. Four RCTs with 1077 SVG patients undergoing the implantation of DES were collected in the current meta-analysis. As a result, second-generation DES-treated patients had the significantly lower MACE rates at 12months (P=0.03; OR: 0.69, 95% CI: 0.49,0.97). No differences in two groups were seen in all-cause death, MI, TVR, stent thrombosis and TLR.CONCLUSIONS:Our limited evidence indicated that, second-generation DES in SVG patients, compared with first-generation DES, offered similar levels of safety, but were more effective than the former one.
The long-term clinical outcomes of intravascular ultrasound-guided versus angiography-guided coronary drug eluting stent implantation in long de novo coronary lesions: A systematic review and meta-analysis

Shen Wang,Changzai Liang,Yue Wang,Shuaifeng Sun,Yue Wang,Min Suo,Maomao Ye,Xinjian Li,Xinyan Liu,Meng Zhang,Xiaofan Wu

DOI: https://doi.org/10.3389/fcvm.2022.944143

IF: 3.6

2022-08-05

Frontiers in Cardiovascular Medicine

Abstract:Background: No meta-analysis has been conducted to compare the long-term clinical outcomes of intravascular ultrasound (IVUS)-guided versus angiographic-guided drug-eluting stent implantation in patients with long de novo coronary lesions. We attempted to compare the efficacy and safety of IVUS guidance versus angiography guidance in percutaneous coronary intervention (PCI) for long de novo coronary lesions. Materials and Methods: We performed a detailed meta-analysis from four randomized controlled trials (RCTs) and one observational study to compare long outcomes of IVUS versus angiography in guiding coronary stent implantation with long de novo coronary lesions defined as coronary stenosis which need stent implantation >28 mm in length. Data were aggregated for the endpoints measure using the fixed-effects model as pooled odds ratio (OR) with 95% confidence intervals. Clinical outcomes included major adverse cardiovascular events (MACE), all revascularization, including target lesion revascularization (TLR) and target vessel revascularization (TVR), all myocardial infarction (MI), all-cause death, and stent thrombosis (ST). Cochrane Library, Embase, PubMed, and Web of Science were searched. Results: Four RCTs and one observational study were included in our study with 3,349 patients (IVUS guidance = 1,708; Angiography guidance = 1,641). With mean follow-up of 2 years, the incidence of MACE, all myocardial infarction, all revascularization and stent thrombosis were significantly lower in IVUS-guided DES implantation of patients with long de novo coronary lesions than in angiography-guided patients; MACE [OR 0.41; 95% confidence interval (CI), 0.29–0.58; p < 0.00001], all myocardial infarction (OR 0.23; 95% CI, 0.09–0.58; p = 0.002), all revascularization (OR 0.48; 95% CI, 0.36–0.66; p < 0.00001), stent thrombosis (OR 0.32; 95% CI, 0.11–0.89; p = 0.03). There was no significant difference in all-cause mortality between the two groups (OR 0.82; 95% CI, 0.55–1.23; p = 0.34). Conclusion: During mean follow-up of 2 years, the incidence of MACE, stent thrombosis, all myocardial infarction and revascularization in patients with long de novo coronary lesions under IVUS-guided PCI were significantly lower than angiography-guided PCI, and there were no statistically significant differences in all-cause mortality.

cardiac & cardiovascular systems
Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent for Coronary Artery Disease

Li Shen,Wei Yang,Jia-Sheng Yin,Xue-Bo Liu,Yi-Zhe Wu,Ai-Jun Sun,Ju-Ying Qian,Jun-Bo Ge

DOI: https://doi.org/10.4103/0366-6999.152490

2015-01-01

Abstract:BACKGROUND:Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to be a promising surrogate of sirolimus to improve DES performance. This randomized controlled trial was to evaluate the efficacy and safety of a novel arsenic trioxide-eluting stent (AES), compared with traditional sirolimus-eluting stent (SES).METHODS:Patients with symptoms of angina pectoris were enrolled and randomized to AES or SES group. The primary endpoint was target vessel failure (TVF), and the second endpoint includes rates of all-cause death, cardiac death or myocardial infarction, target lesion revascularization (TLR) by telephone visit and late luminal loss (LLL) at 9-month by angiographic follow-up.RESULTS:From July 2007 to 2009, 212 patients were enrolled and randomized 1:1 to receive either AES or SES. At 2 years of follow-up, TVF rate was similar between AES and SES group (6.67% vs. 5.83%, P = 0.980). Frequency of all-cause death was significantly lower in AES group (0 vs. 4.85%, P = 0.028). There was no significant difference between AES and SES in frequency of TLR and in-stent restenosis, but greater in-stent LLL was observed for AES group (0.29 ± 0.52 mm vs. 0.10 ± 0.25 mm, P = 0.008).CONCLUSIONS:After 2 years of follow-up, AES demonstrated comparable efficacy and safety to SES for the treatment of de novo coronary artery lesions.
Can "hybrid Stent Implantation" Improve Long-Term Safety Without Adversely Affecting Efficacy when Treating Multilesion Coronary Artery Disease in the Drug-Eluting Stent Era?

Dong Zhang,Kefei Dou,Bo Xu,Yuejin Yang,Jilin Chen,Shubin Qiao,Yang Wang,Jianjun Li,Xuewen Qin,Min Yao,Haibo Liu,Yongjian Wu,Jue Chen,Jinqing Yuan,Shijie You,Wei Li,Runlin Gao

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20123441

IF: 6.133

2013-01-01

Chinese Medical Journal

Abstract:Background Though drug-eluting stent (DES) almost solved a problem of restenosis, safety issues related to stent thrombosis are still the major concern of DES. We hypothesized that hybrid stent implantation may decrease the use of DES, probably improving the long-term safety but not affecting efficacy adversely when treating multilesion coronary artery disease in the DES era.Methods From April 2004 to October 2006, 848 patients with multilesion disease underwent hybrid stent implantation. During the same period 5647 patients with multilesion coronary heart disease were treated by exclusive DES implantation in Fu Wai Hospital. According to propensity score matching, we chose 823 pairs of patients with multileison coronary artery disease for inclusion into our study. We obtained the 24-month clinical outcome including death, myocardial infarction (MI), thrombosis, target lesion revascularization (TLR), target vessel revascularization (TVR), and major adverse cardiac events (MACE, the composite of death, MI, and TVR). We used Cox's proportional-hazard models to assess relative risks of all the outcome measures after propensity match.Results At 24 months, patients in the hybrid stent implantation group showed a significantly higher risk of TLR (8.39% vs. 3.28%, HR 2.38, 95% CI: 1.50-3.70), TVR (11.07% vs. 6.32%, HR 1.61, 95% CI: 1.15-2.27) and MACE (13.75% vs. 8.75%, HR 1.37, 95% CI: 1.02-1.85). No significant difference was apparent in terms of mortality (1.22% vs. 1.70%, HR 0.55, 95% CI: 0.24-1.25), MI (1.95% vs. 2.31%, HR 0.73, 95% CI: 0.37-1.42), or thrombosis (definite+probable) (0.73% vs. 1.58%, HR 0.40, 95% CI: 0.15-1.05).Conclusions In patients with multilesion coronary artery disease, the exclusive DES implantation was associated with significantly lower risks of TLR, TVR and MACE, and the hybrid stent implantation did not result in any significant improvements regarding safety issues. Prospective studies are needed to confirm our results.
Real Polymer-Free Sirolimus- and Probucol-Eluting Versus Biodegradable Polymer Sirolimus-Eluting Stents for Obstructive Coronary Artery Disease: Dkplus-Wave 1, A Multi-Center, Randomized, Prospective Trial

Shao-Liang Chen,Fei Ye,Jun-Jie Zhang,Jian-Jun Zou,Xue-Song Qian,Feng Li,Song Yang,Zhen Ge,Shou-Jie Shan,Xiao-Bo Li,Tian Xu,Jing Kan,Ling Lin,Ya-Ling Han

DOI: https://doi.org/10.1111/j.1755-5922.2012.00319.x

2013-01-01

Cardiovascular Therapeutics

Abstract:BACKGROUND:Polymer-free sirolimus- and probucol-eluting stents (Real Dual drug-eluting stents [DES]) is as effective as first-generation DES in treating coronary artery stenosis. It is unknown whether sirolimus-eluting stents containing biodegradable polymer (Excel) would be superior to real Dual DES. This study aimed to investigate the difference in target vessel revascularization (TVR) at 12 months in patients with coronary artery disease treated by the implantation of Dual DES or Excel stents.METHODS:Three hundred and forty-six patients with de novo coronary artery disease were recruited from six centers in China and randomly assigned to either the Dual DES or the Excel group. The primary endpoint was the occurrence of TVR at 12 months. The secondary endpoint was angiographic in-stent restenosis and late lumen loss at 13 months. Stent thrombosis (ST) served as the safety endpoint. Dual anti-platelet therapy (DAPT) was prescribed for 6 months.RESULTS:Clinical follow-up for 12 months and repeat angiography at 13 months were available in 100% and >90% of patients, respectively. The ISR and in-stent late loss were significantly different between the Excel (3.1%, 0.09 ± 0.11 mm) and the Dual DES (19.5%, 0.36 ± 0.32 mm, P < 0.001, P < 0.001, respectively) groups. The TVR (3.5%) in the Excel group was significantly less than in the Dual DES group (13.9%, P = 0.001). The ST rate beyond 12 months in the Dual DES group was 0%, and this was 1.2% in the Excel group (P = 0.499).CONCLUSIONS:The Excel stent was statistically superior to the Dual DES in terms of restenosis, late loss, and TVR for long lesions.
Long-term clinical outcomes of successful revascularization with drug-eluting stents for chronic total occlusions: A systematic review and meta-analysis.

Lei Gao,Yabin Wang,Yuqi Liu,Feng Cao,Chen Y

DOI: https://doi.org/10.1002/ccd.26934

IF: 2.3

2017-01-01

Catheterization and Cardiovascular Interventions

Abstract:Objectives: To determine whether successful percutaneous coronary intervention (PCI) using drug-eluting stents (DESs) have beneficial effects on long-term outcomes in patients with chronic total occlusions (CTOs) compared with failed PCIs for CTOs. Background: Several observational studies have evaluated the long-term clinical outcomes of successful PCIs using DESs for CTOs. However, the results of these studies were inconsistent and inconclusive. Methods: We searched five online electronic data-bases to identify all the publications assessing the long-term outcomes of successful and failed PCIs using DESs for CTOs. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by STATA software. Results: A total of nine studies involving 5958 CTO patients who underwent successful PCI and 1511 CTO patients who underwent failed PCI were included in this meta-analysis. The results of the analysis indicated that successful CTO PCIs using DESs were associated with lower long-term all-cause mortality(OR = 0.55, 95% CI = 0.45-0.67, P < 0.001), lower risk of myocardial infarction (OR = 0.45, 95% CI = 0.23-0.74, P = 0.002), lower risk of major adverse cardiac events (MACEs, OR = 0.44, 95% CI = 0.27-0.72, P = 0.001), and less incidence of subsequent coronary artery bypass grafting (OR = 0.10, 95% CI = 0.05-0.21, P < 0.001) than failed CTO PCIs. However, there was no difference in the incidence of target vessel revascularization (OR = 1.06, 95% CI = 0.17-6.60, P> 0.05) between the two groups. Conclusion: Successful CTO PCI using DESs can reduce long-term all-cause mortality and the risks of MI, MACEs, and CABG in patients with CTOs. (C) 2017 Wiley Periodicals, Inc.
First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

Geng Wang,Zhongwei Sun,Quanmin Jin,Kai Xu,Yi Li,Xiaozeng Wang,Yingyan Ma,Haiwei Liu,Xin Zhao,Bin Wang,Jie Deng,Shaoyi Guan,Meiling Ge,Xiaoyan Wang,Bo Xu,Yaling Han

DOI: https://doi.org/10.1002/ccd.25862

IF: 2.3

2015-01-01

Catheterization and Cardiovascular Interventions

Abstract:ObjectiveTo evaluate the preliminary safety and efficacy of the EXCEL II stent system.BackgroundAlthough the first biodegradable polymer drug‐eluting stent (BP‐DES), EXCEL, was launched nearly a decade ago, in‐stent restenosis and stent thrombosis remain pertinent clinical problems in practice. A new cobalt‐chromium BP‐DES EXCEL II has been developed with the aim of improving stent safety and efficacy.MethodsForty‐five patients with single de novo native coronary lesions were enrolled and randomized to two groups in a 2:1 ratio, the 4‐month follow‐up group (n = 30) and the 12‐month follow‐up group (n = 15). All patients underwent percutaneous coronary intervention (PCI) with the EXCEL II stent system. Quantitative coronary angiography (QCA) and optical coherence tomography (OCT) were used to assess coronary vasculature at the designated 4‐ or 12‐month follow‐up. The primary outcome was major adverse cardiac events (MACE) at 30 days post‐PCI.ResultsNo MACE, thrombotic events, or target lesion failure was found in the 45 patients during the 12‐month follow‐up. There was no significant difference (P > 0.05) between the two groups in terms of in‐stent and in‐segment late lumen loss (LLL). No in‐stent and in‐segment restenosis was found in either group. At follow‐up, the ratio of >10% uncovered struts per lesion was 26.67% in the 4‐month group and 0% in the 12‐month group (P < 0.05). Neointimal coverage in the 12‐month group was significantly better than in the 4‐month group (98.58% vs. 93.51%, P < 0.01).ConclusionsThis first‐in‐man study demonstrates promising feasibility, safety, and efficacy of EXCEL II stents. These stents were found to have rapid endothelialization and low LLL rates at 4 and 12 months after implantation. © 2015 Wiley Periodicals, Inc.

Male pseudohermaphroditism and pure gonadal dysgenesis in sisters.

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis

Ten-year major clinical outcomes between first- and second-generation drug-eluting stents in hypertensive patients underwent percutaneous coronary intervention

Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials

Comparison of Drug-Eluting Stents with Bare Metal Stents Implantation for the Treatment of Acute ST-elevation Myocardial Infarction: 2-Year Clinical Outcomes from Single-Center Registry.

Effect of Drug Eluting stent Implantation in the Treatment of Coronary Artery In-stent Restenosis in a Longterm Clinical Follow-up

Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis

Protease‐catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix‐assisted laser desorption/ionization mass spectrometry

Drug-coated balloon angioplasty versus drug-eluting stent implantation in ACS patients with different angiographic patterns of in-stent restenosis

Comparison of Clinical Outcomes Between Second-and First-Generation Drug-Eluting Stents in Patients With Chronic Total Occlusion Lesion: A Meta-Analysis

Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis

Second-generation Versus First-Generation Drug-Eluting Stents in Saphenous Vein Graftdisease: A Meta-Analysis of Randomized Controlled Trials.

The long-term clinical outcomes of intravascular ultrasound-guided versus angiography-guided coronary drug eluting stent implantation in long de novo coronary lesions: A systematic review and meta-analysis

Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent for Coronary Artery Disease

Can "hybrid Stent Implantation" Improve Long-Term Safety Without Adversely Affecting Efficacy when Treating Multilesion Coronary Artery Disease in the Drug-Eluting Stent Era?

Real Polymer-Free Sirolimus- and Probucol-Eluting Versus Biodegradable Polymer Sirolimus-Eluting Stents for Obstructive Coronary Artery Disease: Dkplus-Wave 1, A Multi-Center, Randomized, Prospective Trial

Long-term clinical outcomes of successful revascularization with drug-eluting stents for chronic total occlusions: A systematic review and meta-analysis.

First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1